# STATE OF MAINE DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION OFFICE OF PROFESSIONAL AND OCCUPATIONAL REGULATION 35 STATE HOUSE STATION AUGUSTA, MAINE

Janet T. Mills Governor Anne L. Head, Esq. Commissioner

Maine Board of Pharmacy Minutes of September 5, 2024, Board Meeting

04333-0035

Virtual Meeting Public Notification and Hearing/Viewing Instructions Provided at the Opening of the Meeting by Board President Edward Kane.

# **CALL TO ORDER**

President Kane called the meeting to order at 8:34 a.m.

# **MEMBERS PRESENT**

Edward Kane, Esq., Public Member, Board President Nicholas Haar, PharmD, R.Ph., Hospital Pharmacist Timothy McCormack, Esq., Public Member – *Arrived at 8:50 a.m.* Cassandra White, PharmD, R.Ph., Pharmacist Bradley Hamilton, R.Ph., Chain Pharmacist, Complaint Officer

# **MEMBERS ABSENT**

Eric Norberg, RPh, Pharmacist, Vice President Abdifatah Ahmed, PharmD, R.Ph., Independent Pharmacist

# STAFF PRESENT

Geraldine L. Betts, Administrator
Thomas Avery, Chief Field Investigator
Jennifer Willis, Assistant Attorney General, Board Counsel
Meagan McLaughlin, Comprehensive Health Planner II
Clark Phinney, Comprehensive Health Planner II
Dominic Cotone, Comprehensive Health Planner I

# GORDON SMITH, OFFICE OF THE GOVERNOR, DIRECTOR OF OPIOID RESPONSE

Mr. Smith provided the Board with a progress update. He thanked them for their continued efforts. Mr. Smith also reported that September is National Recovery Month and let Board members know that Naloxone is becoming more visible in stores and informed Board members that overdose deaths are now down by 13 percent as of July of 2024.



Maine Board of Pharmacy September 5, 2024, Minutes 2 | P a g e

# MINUTES REVIEW AND APPROVAL

Hamilton moved to accept the minutes of June 6, 2024, with the correction of travel to be removed, seconded by Haar. Kane and McCormack in favor, White abstained, Norberg and Ahmed absent.

Hamilton moved to accept the minutes of August 1, 2024, as presented, seconded by White. Haar, Kane and McCormack in favor, Norberg and Ahmed absent.

# APPLICATION, REVIEW AND BOARD ACTION

Amanda L. Reeder (Initial)

McCormack moved to preliminarily deny licensure to Amanda L. Reeder, PT60018751, and offer a Consent Agreement to include the following 1) Admission to violation of 32 M.R.S. § 13742-A(1)(A), 2); 2) Probation of at least two years, during the first nine months after execution of this agreement, Applicant will obtain, at Applicant's own expense, an alcohol and substance misuse evaluation from a pre-approved, licensed health care practitioner with training in substance misuse diagnosis and treatment, or from a pre-approved medical professional's health program, and authorize the provider to submit the results of the evaluation to the Board. If ongoing treatment or monitoring is recommended, Applicant agrees to submit the treatment and monitoring terms to the Board. Applicant agrees to follow all terms of the proposed treatment and monitoring requirements until its completion, agrees to ensure that quarterly reports of compliance with the treatment and monitoring terms will be submitted by the provider to the Board; and agrees to execute all waivers to all practitioners to share required information with the Board. In addition, if the treatment and monitoring terms continue beyond the period of two years, the Applicant agrees to extend the period of probation until the completion of all treatment and monitoring terms. The applicant also agrees as a condition of probation to comply with any court-ordered bail conditions, treatment, or programming related to this offense, including completion of the DEEP program. Completion of the DEEP program or any other court-ordered condition is separate from and cannot be substituted for the evaluation required under this consent agreement. Seconded by Hamilton. Haar, Kane and White in favor, Norberg and Ahmed absent.

# Leanna J. Manuel (Initial)

McCormack moved to preliminarily deny renewal licensure to Leanna J. Manuel, PT600019098, with offer of a Consent Agreement to include the following: 1) Admission to violation of 32 M.R.S. § 13742-A(1)(A); 2) Probation where Applicant's license shall be subject to a period of probation of at least two (2) years, during the first nine (9) months following licensure the Applicant must obtain, at Applicant's own expense, an evaluation from MPHP, or a preapproved, licensed health care practitioner with training and experience in substance misuse diagnosis and treatment, and to provide that evaluation to the Board; if ongoing treatment or monitoring is recommended, Applicant agrees to submit the treatment and monitoring terms to the Board, agrees to ensure that quarterly reports of compliance will be submitted to the Board, and agrees to follow all terms of the proposed treatment and monitoring requirements until its completion; if the treatment and monitoring requirements recommended by the evaluator last longer than the minimum period of probation, the period of probation shall continue until the Applicant has complied with and completed all recommended treatment and monitoring recommended by the evaluator; the Applicant agrees to execute all waivers to all practitioners to

Maine Board of Pharmacy September 5, 2024, Minutes 3 | P a g e

share required information with the Board. Seconded by Haar. Hamilton, Kane and White in favor, Norberg and Ahmed absent.

# Robert A. Cattan Jr. (Renewal)

McCormack moved to preliminarily deny renewal licensure to Robert A. Cattan Jr. PR4646, with offer of a Consent Agreement to include the following: 1) Admission to violation of 32 M.R.S. § 13742-A(1)(A); 2) Probation where Applicant's license shall be subject to a period of probation of at least two (2) years. Within 4 months of the execution of this Consent Agreement, obtain, at Applicant's own expense, a substance misuse evaluation from a pre-approved, licensed health care practitioner with training and experience in substance misuse diagnosis and treatment, and if ongoing treatment or monitoring is recommended, Applicant agrees to submit the evaluation and treatment and monitoring terms to the Board, agrees to ensure that quarterly reports of compliance will be submitted to the Board, and agrees to follow all recommendations from the evaluator for treatment and monitoring until the evaluator recommends ending the treatment and monitoring; and agrees to execute all waivers to all practitioners to share required information with the Board. Seconded by Hamilton. Haar, Kane and White in favor, Norberg and Ahmed absent.

# Arslan Arif (Exam Eligibility)

White moved to approve NAPLEX exam eligibility request of Arslan Arif, seconded by McCormack. Kane in favor, Haar and Hamilton opposed, Norberg and Ahmed absent.

# LICENSEE SURRENDER REQUEST

Brookfield Pharmaceuticals LLC

Hamilton moved to accept the surrender request of Brookfield Pharmaceuticals LLC, MF30002083, pursuant to 5 M.R.S. Section 8003(5-A)(E). Seconded by White. Haar, Kane, McCormack in favor. Norberg and Ahmed absent.

# COMPLAINT PRESENTATION(S) AND BOARD ACTION

2023-PHA-19522

White moved to dismiss 2023-PHA-19522 with no evidence of a violation of the Board's Laws and Rules, seconded by Haar. Kane and McCormack in favor. Complaint Officer Hamilton recused, Norberg and Ahmed absent.

#### 2023-PHA-19707

White moved to dismiss 2023-PHA-19707 with no evidence of a violation of the Board's Laws and Rules, seconded by Haar. Kane and McCormack in favor. Complaint Officer Hamilton recused, Norberg and Ahmed absent.

# 2024-PHA-20078

White moved to schedule 2024-PHA-20078 for an adjudicatory hearing and to offer a Consent Agreement to include the following: 1) Admission to violation of 32 M.R.S. § 13742-A(1)(C). 2) Warning; 3) Civil Penalty in the amount of \$500.00 and 4) Completion of four (4) hours of continuing education comprised of one (1) hour continuing education regarding avoiding sexual harassment, one (1) hour continuing education regarding confidentiality of protected health information, one (1) hour continuing education regarding ethical duties to patients, and one (1)

Maine Board of Pharmacy September 5, 2024, Minutes 4 | P a g e

hour continuing education regarding patient interactions. all from an accredited provider of Continuing Pharmacy Education. Licensee agrees to notify employer of this complaint and provide a copy of this Consent Agreement. The continuing education credits may not be used to fulfill the continuing education required for re-licensure, seconded by McCormack. Haar and Kane in favor. Complaint Officer Hamilton recused, Norberg and Ahmed absent.

#### RULEMAKING – PROPOSED CHAPTER 4-B: LICENSURE BY ENDORSEMENT

McCormack moved to add Chapter 4-B, Licensure by endorsement to sub-committee for all chapter's rulemaking, seconded by Hamilton. Haar, Kane and White in favor, Norberg and Ahmed absent.

#### CENTRAL FILL PILOT PROJECT PROPOSAL

Board agreed to turn the matter of the request for a rule amendment to the Rules sub-committee meeting for discussion on September 16, 2024 and to schedule a board meeting for September 16, 2024 after the sub-committee meeting to consider any recommendation.

# WAIVER REQUEST

Hamilton moved to approve Aroostook Apothecary LLC, PH50001672, waiver request of Board Rule Chapter 13, Section 3(4) through December 31, 2025, seconded by McCormack. Haar, Kane and White in favor, Norberg and Ahmed absent.

# PUBLIC OPPORTUNITY TO COMMENT

No public comment.

# **ADJOURN**

There being no further business to discuss, Hamilton moved to adjourn the meeting, seconded by White. Haar, Kane and McCormack in favor, Norberg and Ahmed absent.

Meeting adjourned at 11:05 a.m.

Prepared By: Meagan McLaughlin, Comprehensive Health Planner II Board approved: